Business Wire - October 31, 2002
The results of these in vitro studies were presented yesterday at the Therapies for Viral Hepatitis Conference in Boston. In the studies, human cells infected with HBV were treated with either ZADAXIN, lamivudine, or placebo and cells infected with HIV were treated with either ZADAXIN, AZT, or placebo. In both studies, cells treated with ZADAXIN showed reduced viral replication. This demonstrates for the first time that ZADAXIN has direct antiviral effects on HBV and HIV infected cells, in addition to its ability to stimulate the immune system.
Dr. Cynthia Tuthill, Vice President of Scientific Affairs of SciClone Pharmaceuticals, commented, "Taken together, these data demonstrate direct antiviral activity of ZADAXIN against HBV and HIV. This mechanism of action supports the exploration of ZADAXIN in the therapy of patients coinfected with HBV and HIV."
About SciClone
SciClone Pharmaceuticals is a biopharmaceutical company and its lead product ZADAXIN, an Immune System Enhancer, is in two phase 3 hepatitis C clinical trials in the U.S., a phase 3 hepatitis B clinical trial in Japan, a phase 2 malignant melanoma clinical trial in Europe, and two phase 2 liver cancer clinical trials in the U.S.
ZADAXIN has been approved for sale by the ministries of health in over 30 countries and is marketed in China and selected other countries outside the U.S. ZADAXIN has been administered to more than 10,000 patients in both clinical and commercial use, alone and in combination with antiviral and anticancer drugs, without producing any ZADAXIN related significant side effects or toxicities.
SciClone's strategic goal is to become a principal worldwide provider of Immune System Enhancers (ISE) both as monotherapies and as critical components of combination drug therapies for infectious diseases and cancer. SciClone's other drug development opportunities include an orally available ISE and products to address the protein-based disorder that causes cystic fibrosis.
This press release contains forward-looking statements including statements regarding the potential of ZADAXIN. Clinical and experimental data is not necessarily predictive of the efficacy and safety of ZADAXIN.
CONTACT: SciClone
Richard A. Waldron, 650/358-3437
SOURCE: SciClone
021031
BW021016
Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .